This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

The Effect of Surgically Induced Weight Loss on Endocrine Function, Cardiovascular Function and Body Composition

This study has been terminated.
(PI left JHU)
Sponsor:
Information provided by (Responsible Party):
Johns Hopkins University
ClinicalTrials.gov Identifier:
NCT00686972
First received: May 27, 2008
Last updated: June 1, 2017
Last verified: June 2017
Results First Received: May 1, 2017  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Other
Condition: Bariatric Surgery
Intervention: Drug: GLP-1

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Glucagon Like Peptide 1 -GLP-1

5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.

GLP-1: 5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.


Participant Flow:   Overall Study
    Glucagon Like Peptide 1 -GLP-1
STARTED   51 
COMPLETED   0 
NOT COMPLETED   51 
P.I, Left institution. Study terminated                51 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
GLP-1

5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.

GLP-1: 5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.


Baseline Measures
   GLP-1 
Overall Participants Analyzed 
[Units: Participants]
 51 
Age, Customized 
[Units: Participants]
 
>=21 and <=65   51 
Sex: Female, Male 
[Units: Participants]
Count of Participants
 
Female      43  84.3% 
Male      8  15.7% 
Region of Enrollment 
[Units: Participants]
 
United States   51 


  Outcome Measures

1.  Primary:   Insulin Secretion   [ Time Frame: 2 years ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Johns Hopkins University Clinical Trials Program
Organization: Johns Hopkins University School of Medicine
phone: 410-550-6484
e-mail: registerclinicaltrials@jhmi.edu



Responsible Party: Johns Hopkins University
ClinicalTrials.gov Identifier: NCT00686972     History of Changes
Other Study ID Numbers: NA_00004876
Study First Received: May 27, 2008
Results First Received: May 1, 2017
Last Updated: June 1, 2017